product
procedur
viral
vaccin
gene
therapi
vector
one
strike
exampl
develop
cell
culturederiv
influenza
vaccin
convent
product
process
reli
eggbas
system
optim
cell
cultur
system
current
establish
cope
sudden
demand
pandem
vaccin
increas
suppli
season
vaccin
advanc
upstream
procedur
increas
yield
harvest
volum
influenza
vaccin
well
vaccin
viral
vector
downstream
process
dsp
becom
import
factor
race
higher
overal
product
decreas
cost
good
gener
aim
dsp
recoveri
purif
biolog
product
processand
productrel
impur
processrel
impur
might
origin
cell
cultur
reagent
addit
eg
antibiot
bovin
serum
albumin
benzonas
merck
kgaa
darmstadt
germani
purif
process
eg
extract
leachabl
chromatographi
cell
substrat
eg
host
cell
protein
nucleic
acid
proteoglycan
glycosaminoglycan
exampl
viru
particlerel
impur
includ
free
envelop
protein
viru
aggreg
empti
capsid
viru
particl
contain
nucleic
acid
sequenc
intend
viru
particl
current
use
medic
analyt
scientif
applic
bioinsecticid
recent
medic
applic
gain
increas
interest
owe
grow
market
viral
vaccin
tabl
potenti
broad
usag
viral
gene
therapi
vector
vaccin
administ
prevent
treat
viral
diseas
mainli
base
attenu
kill
virus
membran
fraction
deriv
purifi
viru
particl
recombin
viral
protein
express
variou
host
exampl
success
attenu
kill
viru
vaccin
influenza
measl
mump
rubella
rotaviru
yellow
fever
varicella
gene
therapi
involv
transfer
genet
inform
cell
tissu
individu
achiev
therapeut
effect
therefor
requir
gene
larg
deliv
viral
vector
system
base
exampl
herp
simplex
viru
adenoviru
adenoassoci
viru
aav
retroviru
eg
lentiviru
vaccinia
viru
current
numer
clinic
gene
therapi
trial
conduct
investig
treatment
diseas
cancer
cystic
fibrosi
alzheim
parkinson
hemophilia
hivaid
broad
spectrum
applic
current
expans
medic
market
underlin
ongo
effort
improv
review
genom
natur
requir
product
puriti
product
safeti
depend
particular
applic
vaccin
viral
vector
need
meet
stringent
guidelin
regulatori
author
us
fda
ema
virus
complex
bioparticl
vari
size
shape
composit
surfac
structur
viru
surfac
defin
individu
physicochem
characterist
includ
number
distribut
charg
hydrophob
residu
posttransl
modif
ie
glycan
surfac
protein
purif
viru
particl
base
uniqu
characterist
remov
contamin
accord
regulatori
guidelin
achiev
combin
differ
unit
oper
articl
provid
overview
individu
unit
oper
current
use
dsp
viral
vaccin
gene
therapi
vector
includ
method
precipit
floccul
extract
centrifug
microfiltr
ultrafiltr
beadbas
membranebas
chromatographi
use
monolith
addit
address
issu
concern
use
continu
chromatographi
method
simul
move
bed
chromatographi
util
kit
smalland
mediumscal
purif
concentr
viru
particl
vector
gene
therapi
final
exampl
complet
purif
train
present
dsp
viru
particl
therapeut
applic
vaccin
manufactur
owe
complex
larg
bioparticl
necess
maintain
specif
immunogen
infect
viru
particl
viral
vector
precipit
floccul
rare
use
dsp
even
purif
recombin
protein
use
method
consid
problemat
owe
potenti
loss
biolog
activ
howev
latest
advanc
upstream
process
recombin
protein
term
high
cell
densiti
cultur
drastic
improv
product
level
trigger
reevalu
method
particularli
purif
monoclon
antibodi
turkey
coronaviru
precipit
ammonium
sulfat
low
recoveri
compar
ultracentrifug
sucros
cushion
viru
particl
precipit
vari
combin
polyethylen
glycol
peg
sodium
chlorid
particular
peg
precipit
bovin
rotaviru
particl
result
approxim
tenfold
better
yield
pellet
highspe
centrifug
base
result
determin
tissu
cultur
infect
dose
tcid
assay
could
owe
increas
damag
viru
particl
highspe
centrifug
irrevers
aggreg
viru
particl
lead
overal
reduc
tcid
measur
furthermor
precipit
aav
vector
via
peg
lead
enhanc
puriti
compar
classic
conduct
cesium
chlorid
cscl
gradient
ultracentrifug
altern
precipit
target
viru
remov
contamin
host
cell
dna
protein
crude
cultur
harvest
recent
studi
focus
precipit
host
cell
dna
clarifi
cultiv
broth
influenza
viru
particl
conduct
et
al
investig
cation
reagent
respect
abil
select
precipit
host
cell
dna
observ
success
dna
reduct
appli
cation
polym
protamin
sulfat
polyethyleneimin
howev
discuss
author
acid
isoelectr
point
influenza
viru
particl
tabl
may
result
coprecipit
viru
particl
cation
polym
therefor
product
loss
past
effect
purif
encephalomyocard
viru
cellular
compon
remov
cellular
dna
polioviru
produc
continu
cell
line
well
prepar
inactiv
vaccin
tickborn
enceph
protamin
sulfat
precipit
demonstr
consid
continu
effort
increas
harvest
volum
cell
concentr
vaccin
gene
therapi
vector
product
precipit
repres
interest
approach
reduct
high
load
host
cell
dna
protein
howev
process
robust
ie
specif
appli
precipit
need
improv
nontox
compound
precipit
process
need
identifi
econom
applic
pharmaceut
product
hepat
c
viru
flavivirida
na
spheric
ye
ssrna
herp
simplex
viru
ye
dsdna
influenza
viru
orthomyxovirida
pleomorph
spheric
ye
ssrna
retrovirida
na
spheric
ye
ssrna
papillomaviru
papillomavirida
papillomaviru
icosahedr
dsdna
polioviru
picornavirida
icosahedr
ssrna
precipit
system
complex
mainli
depend
structur
physicochem
divers
viru
particl
constrain
techniqu
becom
wide
use
drawback
appli
extract
method
purif
viru
particl
possibl
loss
viral
infect
immunogen
transduct
effici
high
level
coextract
contamin
high
cost
recycl
util
organ
solvent
nevertheless
extract
via
aqueou
twophas
system
peg
dextran
salt
polyvenyl
alcohol
use
separ
viru
particl
cultiv
medium
exampl
applic
purif
concentr
adenoviru
bovin
leukemia
viru
felin
leukemia
viru
human
simian
immunodefici
viru
number
public
patent
describ
purif
concentr
viru
particl
centrifug
method
demonstr
procedur
extens
use
industrialand
smallscal
level
viral
vector
vaccin
product
process
industri
scale
continu
flow
centrifug
method
consid
allow
handl
larger
volum
howev
method
requir
high
invest
cost
suffer
case
loss
infect
lead
increas
usag
ultrafiltr
techniqu
particularli
outsid
laboratori
scale
clear
advantag
centrifig
method
potenti
separ
assembl
viral
vector
empti
capsid
commonli
challeng
separ
techniqu
anoth
advantag
dsp
virus
frequent
chang
strain
eg
influenza
centrifug
method
robust
relat
viral
strain
differ
result
rediscoveri
technolog
number
process
common
centrifug
method
purif
macromolecul
viru
particl
densiti
gradient
centrifug
use
cscl
iodixanol
sucros
gradient
classifi
two
categori
ratezon
separ
isopycn
separ
latter
base
buoyant
densiti
particl
rate
zonal
separ
particl
size
mass
exampl
viru
particl
purifi
gradient
centrifug
techniqu
felin
leukemia
viru
gibbon
ape
lymphoma
viru
hepat
b
viru
influenza
viru
japanes
enceph
viru
mammalian
type
c
viru
mous
mammari
tumor
viru
mous
oncorna
viru
mump
viru
murin
leukemia
viru
tickborn
enceph
viru
turkey
coronaviru
rabi
viru
vaccinia
viru
altern
centrifug
method
differenti
centrifug
pellet
epsteinbarr
viru
hepat
viru
simpl
sediment
onto
sucros
cushion
moloney
murin
sarcoma
viru
done
repeatedli
differ
centrifug
speed
current
exampl
concentr
purif
viru
particl
via
centrifug
adenoviru
aav
bromoviru
hepat
c
viru
herpeslik
viru
retroviru
rotaviru
vaccinia
viru
microfiltr
commonli
use
clarif
biotechnolog
product
process
altern
centrifug
remov
microcarri
produc
cell
cell
debri
organel
dsrna
rubella
viru
togavirida
rubiviru
na
quasispher
ye
ssrna
semliki
forest
viru
connaught
lister
lister
lister
egg
lister
rabbit
wr
ye
dsdna
data
isoelectr
point
differ
virus
taken
michen
graul
brickshap
viral
particl
therefor
dimens
shown
term
axi
xyz
diamet
l
length
na
avail
kda
kda
tangenti
flow
filtrat
millipor
pellicon
ii
filter
modul
polyethersulfon
flat
sheet
kda
provid
tangenti
flow
filtrat
millipor
centrifug
filter
unit
regener
cellulos
flat
sheet
kda
tangenti
flow
filtrat
millipor
pellicon
ii
filter
modul
polyethersulfon
flat
sheet
kda
provid
kda
provid
tangenti
flow
filtrat
individu
setup
polysulfon
gehealthcar
kda
polysulfon
frequent
membran
pore
size
rang
appli
although
techniqu
involv
risk
viral
loss
recoveri
depend
initi
membran
pore
size
type
membran
materi
qualiti
crude
stock
viru
ie
size
viru
subtyp
aggreg
behavior
appli
buffer
condit
filtrat
rate
natur
level
protein
concentr
filtrat
extent
pore
obstruct
demonstr
retrovir
vector
viru
loss
mainli
attribut
mechan
disrupt
particularli
activ
viru
particl
ie
gene
therapi
vector
exclus
viru
particl
membran
entrap
well
unspecif
viru
adsorpt
loss
due
pore
obstruct
reduc
appli
membran
cascad
decreas
pore
size
filter
capsul
dual
membran
minim
membran
foul
appli
larger
membran
area
ie
frequent
chang
filtrat
unit
usag
larger
unit
limit
volum
supernat
per
membran
surfac
ultrafiltr
one
prefer
method
viru
remov
biolog
product
method
viru
concentr
buffer
exchang
vaccin
viral
gene
transfer
vector
manufactur
process
tabl
viru
particl
usual
enrich
maintain
retent
water
smallmolecularweight
molecul
remov
permeat
although
ultrafiltr
low
resolut
size
differ
viru
particl
tabl
compar
solubl
biopolym
ie
nucleic
acid
protein
allow
rel
effici
econom
separ
viru
key
paramet
ultrafiltr
process
transmembran
pressur
tmp
feed
retent
permeat
flux
well
nomin
molecular
weight
limit
also
sometim
refer
molecular
weight
cutoff
mwco
pore
size
defin
mwco
normal
distribut
mean
pore
size
vari
depend
product
method
membran
therefor
also
manufactur
order
minim
product
loss
via
permeat
mwco
significantli
smaller
viru
particl
howev
mwco
select
small
permeat
flux
reduc
lead
longer
filtrat
time
increas
tmp
decreas
possibl
reduc
amount
contamin
protein
nucleic
acid
furthermor
membran
foul
decreas
permeat
flux
often
greater
larger
pore
size
membran
smaller
one
small
viru
particl
also
cell
viru
review
debri
abl
enter
pore
eventu
trap
constrict
channel
asymmetr
ultrafiltr
membran
finer
filter
surfac
face
feed
suspens
appli
possibl
reduc
intern
foul
import
concentr
activ
viru
particl
gentl
process
tmp
retent
flux
optim
low
wall
shear
rate
filtrat
filtrat
perform
particular
permeat
flux
heavili
affect
type
compon
cultiv
medium
therebi
underlin
import
tight
interact
upand
downstream
develop
nowaday
serum
contain
growth
media
rare
use
product
process
serumfre
media
often
contain
defin
protein
bovin
albumin
insulin
also
protein
hydrolys
proteinfre
media
includ
defin
polypeptid
amino
acid
higher
concentr
protein
target
viru
nucleic
acid
larger
size
contamin
dna
fragment
retent
higher
sampl
viscos
lead
continu
decreas
permeat
flux
constant
tmp
addit
high
retent
protein
concentr
result
increas
degre
concentr
polar
also
reduc
permeat
flux
final
ionic
strength
type
ion
ph
suspend
buffer
influenc
siev
coeffici
protein
probabl
also
macromolecular
biomolecul
viru
particl
ultrafiltr
carri
wide
varieti
filtrat
devic
tabl
small
scale
ml
centrifug
filtrat
devic
well
suit
small
medium
volum
ml
stir
cell
tank
ideal
larger
volum
usual
concentr
tangenti
flow
filtrat
three
type
membran
avail
tubular
membran
flat
sheet
cassett
hollowfib
membran
latter
two
commonli
use
biopharmaceut
industri
gener
flatsheet
tubular
tangentialflow
membran
modul
higher
mass
transfer
coeffici
low
crossflow
rate
compar
hollowfib
modul
latter
wide
feed
flow
path
provid
laminar
flow
low
shear
rate
crucial
process
life
vaccin
gene
therapi
vector
high
shear
rate
significantli
reduc
efficaci
overal
yield
gener
advantag
hollowfib
membran
modul
compar
flat
sheet
high
membran
surfacetomodul
volum
ratio
howev
individu
modul
flatsheet
tangentialflow
membran
modul
easier
clean
replac
defect
membran
element
uncompl
overal
type
membran
eventu
use
specif
process
depend
larg
viscos
solid
content
volum
feed
well
product
stabil
shearsensit
thu
concentr
diafiltr
activ
viru
particl
hollowfib
membran
superior
flatsheet
membran
potenti
improv
classic
tangentialflow
filtrat
highperform
tangentialflow
filtrat
achiev
superior
separ
factor
highperform
tangentialflow
filtrat
part
permeat
circul
cocurr
feed
permeat
side
modul
result
constant
tmp
throughout
modul
due
axial
pressur
drop
along
permeat
flow
channel
allow
care
optim
oper
condit
stabl
transmembran
flux
time
case
lead
improv
select
purif
viru
particl
tabl
summari
main
advantag
ultrafiltr
compar
method
highthroughput
concentr
activ
viru
particl
gentl
process
optim
oper
condit
result
improv
efficaci
purif
viral
vector
gene
therapi
anoth
advantag
util
size
differ
viru
particl
solubl
compon
cultur
medium
purif
concentr
broad
applic
among
differ
type
virus
viru
subtyp
differ
recombin
form
viru
open
path
establish
gener
platform
technolog
consid
complet
purif
train
product
vaccin
gene
therapi
vector
figur
current
improv
dynam
bind
capac
chromatographi
media
might
facilit
remov
initi
concentr
step
within
downstream
process
howev
later
concentr
step
buffer
exchang
final
formul
continu
done
via
ultrafiltr
chromatographi
popular
methodolog
largescal
purif
vaccin
viral
gene
therapi
vector
chromatograph
separ
base
differ
interact
target
viru
compon
appli
stationari
phase
specif
characterist
viru
particl
exploit
describ
physicochem
properti
outer
particl
surfac
electrostat
properti
whole
particl
larg
hydrodynam
volum
compar
solubl
process
compon
four
main
point
chromatographi
consid
success
purif
physic
structur
stationari
phase
includ
morpholog
ie
bead
membran
monolith
pore
size
poros
mechan
chemic
properti
eg
resist
pressur
surfac
charg
mobil
phase
specif
resin
particl
size
particl
distribut
surfac
chemistri
stationari
phase
composit
mobil
phase
mode
oper
adsorpt
partit
type
elut
columnh
system
hardwar
applic
balanc
individu
aspect
must
found
obtain
effici
chromatograph
procedur
follow
section
howev
focu
first
two
point
chromatograph
purif
viru
particl
mainli
achiev
use
three
differ
type
stationari
phase
pack
bed
membran
adsorb
monolith
case
pack
bed
matrix
consist
resin
bead
fill
column
biosepar
polym
inorgan
resin
materi
commonli
use
polymerbas
bead
either
consist
natur
polym
agaros
agarosedextran
composit
cellulos
dextran
synthet
polym
polyacrylamid
polystyren
divinylbenzen
deriv
polyacrylamid
deriv
polymethacryl
exampl
inorgan
matric
use
purif
viru
particl
hydroxyapatit
silica
controlledpor
glass
bead
spheric
nonspher
shape
avail
porou
nonpor
solidcor
resin
pore
size
convent
porou
bead
rang
nm
although
specif
particl
pore
diamet
nm
avail
viru
particl
vari
gener
nm
greater
nm
tabl
henc
materi
transport
viru
particl
limit
porediffus
poreexclus
effect
even
small
viru
particl
abl
enter
larg
pore
diffus
intraparticular
channel
twoto
slower
protein
fact
major
chromatographi
resin
current
avail
optim
purif
protein
rather
viru
particl
primarili
adsorb
outer
bead
surfac
furthermor
interparticl
poros
pack
bed
reach
valu
maxim
wherea
stationari
phase
monolith
valu
monolith
continu
stationari
phase
homolog
column
interconnect
channel
allow
convect
flow
mobil
phase
entir
matrix
commerci
avail
monolith
made
polymethacryl
copolym
bia
separ
ljubljana
slovenia
dionex
sunnyval
ca
usa
polyacrylamid
biorad
hercul
ca
usa
protista
biotechnolog
ab
lund
sweden
polystyren
dionex
sunnyval
ca
usa
polystyrenedivinylbenzen
dionex
sunnyval
ca
usa
modifi
cellulos
sepragen
hayward
ca
usa
silica
merck
darmstadt
germani
phenomenex
torrenc
ca
usa
depend
manufactur
sold
disk
tube
rod
pore
size
rang
nm
silica
merck
polymethacryl
bia
separ
membran
materi
chromatograph
biosepar
includ
cellulos
polyamin
polysulfon
hydrazid
composit
membran
polyethylen
oxid
polyethersulfon
coat
hydroxyethylcellulos
three
type
chromatograph
membran
adsorb
use
purif
bioproduct
flat
sheet
eg
pall
dreieich
germani
sartoriu
germani
hollow
fiber
eg
kinet
system
inc
boston
usa
radialflow
devic
eg
neuss
germani
advantag
hollowfib
membran
adsorb
high
surfac
area
reduct
particl
accumul
near
pore
entranc
owe
crossflow
principl
use
separ
howev
breakthrough
target
compound
gener
broaden
lead
poor
adsorb
util
compar
flat
sheet
furthermor
elut
product
heavili
dilut
intern
mix
within
fiber
hous
result
low
resolut
applic
gradient
elut
limit
radialflow
adsorb
flatsheet
membran
spiral
wound
cylindr
core
wherebi
avail
surfac
area
significantli
increas
thu
volumetosurfac
area
spiralwound
membran
adsorb
better
major
hollowfib
adsorb
still
product
dilut
gradient
elut
accordingli
challeng
flat
sheet
mainli
use
stack
numer
individu
sheet
provid
larger
adsorb
volum
flatsheet
membran
adsorb
liquid
commonli
introduc
vertic
membran
adsorb
surfac
allow
minimum
dead
volum
optim
design
membran
modul
thu
membran
adsorb
suffer
dilut
product
fraction
use
gradient
elut
procedur
main
advantag
membran
adsorb
monolith
separ
viru
particl
predomin
convect
materi
transport
nearli
diffus
limit
owe
larg
pore
wellinterconnect
channel
small
constrict
high
dynam
bind
capac
wherebi
latter
sometim
lower
membran
adsorb
compar
monolith
pore
structur
membran
adsorb
monolith
facilit
access
larg
viru
particl
bound
ligand
contrast
typic
resin
exclud
intern
bead
pore
except
monolith
eddi
form
major
chromato
graphic
matric
includ
membran
adsorb
result
labil
viru
particl
deterior
separ
impair
peak
broaden
stack
membran
adsorb
ac
sulfat
cellulos
sulfat
cellulos
ac
sartobind
znida
ac
differ
ligand
immobil
monolith
provid
parvovirida
aed
aegypti
densonucleosi
viru
sartobind
q
sartobind
c
provid
parvovirida
adenoassoci
viru
retrovirida
vector
momlvderiv
vsvgpseudotyp
retrovir
vector
ac
fractogel
emd
heparin
filtrat
uf
df
ac
sec
fractogel
emd
heparin
sepharos
retrovirida
vector
momlvderiv
vsvgpseudotyp
retrovir
vector
ac
fractogel
emd
heparin
retrovirida
vector
momlvderiv
retrovir
vector
ac
fractogel
emd
heparin
retrovirida
vector
vsvg
pseudotyp
human
immunodefici
viru
type
vector
aec
mustang
q
sec
sephacryl
retrovirida
vector
vsvgpseudotyp
retrovir
vector
sec
sepharos
uf
sec
ufdf
sepharos
retrovirida
vector
tag
retrovir
vector
ninta
agaros
retrovirida
vector
biotintag
retrovir
vector
ac
fractogel
emd
streptavidin
steptavidinmonolith
retrovirida
review
consid
thin
slice
monolith
pore
membran
layer
connect
void
space
individu
membran
slice
lead
potenti
eddi
format
flow
distribut
hollowfib
radialflow
membran
adsorb
less
well
control
compar
either
monolith
packedb
column
addit
eddi
format
could
result
reduc
dynam
bind
capac
dispers
latter
affect
negativemod
adsorpt
chromatographi
also
reduc
resolut
positivemod
applic
major
membran
adsorb
design
singleus
applic
support
current
effort
pharmaceut
industri
reduc
cost
valid
clean
sanit
monolith
current
follow
trend
bead
howev
remain
seen
dispos
approach
realiz
econom
nevertheless
wider
divers
adsorpt
surfac
chemistri
current
avail
resin
convect
altern
product
rang
membranebas
separ
constantli
expand
current
five
differ
mode
use
chromatograph
separ
viru
particl
sizeexclus
chromatographi
sec
ion
exchang
chromatographi
iec
affin
chromatographi
ac
hydrophobicinteract
chromatographi
hic
mixedmod
chromatographi
tabl
action
principl
possibl
process
optim
limit
stabil
individu
virus
extrem
run
condit
term
ph
osmolar
ion
composit
certain
organ
solvent
might
influenc
efficaci
vaccin
gene
therapi
vector
henc
normal
reversedphas
chromatographi
requir
organ
solvent
usual
appli
wholeviru
separ
howev
split
vaccin
subunit
vaccin
viru
membran
integr
necessarili
conserv
organ
solvent
thu
reversedor
normalphas
chromatographi
might
use
depend
solvent
effect
target
protein
partit
chromatographi
sec
achiev
porou
particl
membran
adsorb
monolith
sec
viru
particl
gener
recov
column
void
volum
allow
separ
bulk
protein
small
molecular
contamin
without
buffer
chang
gentl
oper
condit
therebi
maintain
viru
infect
immunogen
owe
larg
differ
hydrodynam
volum
intact
viru
particl
solubl
contamin
sec
exclus
limit
easili
optim
distinguish
morpholog
similar
virus
allow
robust
process
condit
broad
applic
differ
strain
routin
requir
eg
influenza
vaccin
main
disadvantag
sec
low
capac
product
dilut
poor
pressur
resist
matrix
requir
low
flow
rate
despit
disadvantag
sec
repres
valuabl
method
addit
adsorpt
chromatographi
highthroughput
option
ultrafiltr
process
challeng
applic
unit
oper
separ
viru
particl
futur
industri
chromatographi
process
usual
optim
high
dynam
bind
capac
particularli
primari
captur
step
elimin
residu
contamin
polish
step
figur
high
capac
attain
larg
access
surfac
area
optim
ligand
densiti
high
select
latter
import
highli
contamin
load
ie
feedstock
appli
addit
dynam
bind
capac
ligand
densiti
adsorpt
matric
iec
ac
hic
also
contribut
overal
adsorpt
strength
mainli
due
multival
interact
viru
particl
matrix
ligand
thu
ligand
densiti
need
care
select
take
account
aspect
furthermor
desorpt
condit
need
consid
select
optim
ligand
ligand
densiti
allow
elut
condit
affect
viru
immunogen
transfect
effici
vector
strong
adsorpt
requir
harsh
desorpt
condit
target
viru
particl
often
observ
iec
hic
adsorpt
matric
commonli
use
posit
mode
ie
viru
particl
adsorb
chromatographi
medium
neg
mode
ie
contamin
adsorb
matrix
viru
particl
elut
positivemod
applic
usual
use
captur
intermedi
purif
neg
mode
final
polish
ion
exchang
chromatographi
exploit
chargetocharg
interact
viru
surfac
immobil
ion
exchang
group
matrix
depend
overal
isoelectr
point
tabl
individu
viru
particl
cationor
anion
exchang
chromatographi
aec
matrix
util
differ
variat
iec
appli
purif
varieti
virus
tabl
adsorb
viru
particl
gener
displac
increas
ionic
strength
altern
desorb
chang
buffer
ph
lead
unfavor
overal
charg
viru
surfac
matrix
viru
particl
bind
anymor
iec
rel
low
specif
result
reduc
dynam
bind
capac
target
viru
often
result
coelut
contamin
eg
host
cell
dna
aec
differenti
elut
target
viru
contamin
sometim
achiev
linearor
stepgradi
elut
high
salt
concentr
nonphysiolog
ph
condit
requir
purif
crucial
monitor
immunogen
transfect
effici
viru
particl
henc
iec
matric
care
select
term
type
charg
group
ligand
densiti
appli
buffer
condit
respect
viru
type
product
applic
util
assay
process
character
affin
chromatographi
viru
particl
reli
specif
revers
adsorpt
subsequ
recoveri
activ
target
viru
ligand
immobil
onto
chromatographi
matrix
specif
interact
ligand
viru
base
individu
structur
properti
viru
particl
commonli
elut
alter
conform
via
chang
buffer
ph
ionic
strength
competit
displac
howev
latter
gener
econom
largescal
product
process
frequent
appli
smaller
scale
appli
ligand
matric
purif
viru
particl
immobil
metal
ion
affin
sulfat
carbohydr
eg
heparin
specif
antibodi
antibodi
fragment
biotin
streptavidin
system
recombin
viral
vector
lectin
dna
aptam
peptid
tabl
major
virus
specif
ligand
known
result
applic
lessspecif
ligand
lectin
sulfat
carbohydr
ie
heparin
lectin
interact
access
carbohydr
moieti
surfac
glycoprotein
accord
specif
heparin
primarili
weak
strong
cation
exchang
contain
sulfo
carboxyl
group
well
numer
hydroxyl
group
desorpt
viru
particl
heparin
matric
done
increas
ionic
strength
howev
often
requir
higher
ionic
strength
classic
cation
exchang
owe
multival
interact
branch
linear
structur
heparin
format
hydrogen
bond
target
viru
heparin
altern
labori
ligand
screen
applic
less
specif
pseudoaffin
ligand
engin
viral
vector
contain
affin
tag
viru
surfac
crucial
specif
affin
ligand
consider
dissoci
constant
recombin
protein
dissoci
constant
usual
consid
good
work
rang
optim
affin
ligand
allow
fast
bind
kinet
high
flow
rate
mild
elut
condit
avoid
reduct
immunogen
activ
therefor
essenti
consid
overal
bind
strength
larg
viru
particl
due
alreadi
discuss
multival
interact
protein
larger
biomolecul
use
ligand
potenti
toxic
immunogen
consid
appli
assay
develop
detect
quantif
furthermor
mani
protein
high
cost
associ
low
stabil
ligand
toward
sanit
agent
case
prohibit
applic
largescal
process
case
addit
drawback
specif
ligand
restrict
applic
platform
technolog
limit
process
robust
vaccin
frequent
vari
subtyp
eg
influenza
vaccin
furthermor
virus
vari
progeni
eg
vaccinia
viru
viru
particl
might
exclud
therebi
affect
overal
yield
hand
appli
specif
allow
separ
specif
progeni
ligand
target
posttransl
modif
viru
surfac
heavili
suscept
cultiv
condit
host
cell
henc
target
epitop
ac
matric
viru
surfac
care
select
consid
stabil
entir
process
nevertheless
matric
highli
specif
affin
ligand
high
dynam
bind
capac
well
suit
captur
viru
particl
clarif
low
concentr
cultiv
broth
hydrophobicinteract
chromatographi
separ
biomolecul
depend
differenti
interact
compound
hydrophob
ligand
surfac
stationari
phase
routin
use
biosepar
protein
also
appli
viru
purif
sinc
orthogon
separ
techniqu
purif
method
base
ionic
interact
howev
mani
factor
type
salt
ionic
strength
buffer
ph
temperatur
ligand
ligand
densiti
influenc
perform
hic
make
develop
optim
difficult
timeconsum
endeavor
two
commonli
use
hic
ligand
butyl
phenyl
interact
ligand
rel
strong
frequent
cite
denatur
labil
protein
potenti
reduc
efficaci
howev
often
protein
subject
method
revert
upon
elut
nativ
structur
even
use
purif
gene
transfer
vector
vaccin
transfect
effici
immunogen
close
monitor
high
salt
applic
iec
method
stronger
hic
ligand
hexyl
octyl
commonli
destruct
protein
like
also
viru
particl
gene
therapi
vector
appli
posit
mode
furthermor
hic
requir
applic
high
concentr
kosmotrop
salt
potenti
also
reduc
viru
efficaci
also
applic
high
salt
concentr
influenc
viru
aggreg
major
case
affect
downstream
process
often
process
analyt
addit
disaggreg
form
aggreg
usual
impact
viru
transfect
effici
immunogen
nevertheless
recent
shown
hic
success
appli
remov
residu
dna
ac
purif
activ
vaccinia
viru
particl
mvabn
bavarian
nordic
kvistgaard
denmark
tabl
mixedmod
chromatographi
exploit
multimod
function
allow
viru
particl
contamin
adsorb
stationari
phase
combin
ionic
interact
hydrogen
bond
andor
hydrophob
interact
typic
exampl
mixedmod
chromatographi
media
hydroxyapatit
support
metal
affin
interact
hydroxyapatit
calcium
group
cation
exchang
interact
hydroxyapatit
phosphat
group
success
applic
mixedmod
matric
purif
gene
therapi
vector
describ
adenovirus
aav
moloney
murin
leukemia
virus
retrovirus
tabl
continu
chromatograph
process
simul
move
bed
smb
technolog
today
well
establish
separ
binari
mixtur
petrochem
sugar
small
molecul
pharmaceut
smb
significantli
improv
volumetr
throughput
well
puriti
concentr
factor
rel
batch
chromatographi
howev
purif
complex
biolog
mixtur
still
challeng
system
oper
binari
fraction
provid
two
exit
stream
howev
new
oper
mode
threefract
smb
solvent
gradient
smb
clean
inplac
smb
import
step
lead
way
success
applic
biosepar
final
complex
equip
experiment
setup
larg
number
valv
requir
pose
seriou
challeng
process
valid
design
chromatograph
purif
process
challeng
owe
multitud
unit
oper
process
variabl
constantli
grow
number
avail
matric
differ
chromatographi
mode
divers
oper
condit
result
extrem
larg
amount
design
freedom
exist
far
select
unit
oper
choic
process
condit
reli
mainli
practic
experi
trial
error
approach
order
save
valuabl
time
resourc
miniatur
parallel
screen
tool
develop
combin
addit
kinet
studi
eg
surfac
plasmon
reson
spr
spectroscopi
thermodynam
measur
dynam
lightscatt
ana
lysi
guid
earli
stage
process
develop
optim
select
appropri
experi
paramet
screen
commonli
plan
via
experiment
design
softwar
tool
eg
designexpert
modd
statistica
implement
concept
qualiti
design
furthermor
softwar
tool
computeraid
process
design
product
schedul
process
debottleneck
often
use
date
highthroughput
process
develop
mainli
appli
product
process
recombin
protein
howev
method
also
appli
dsp
viral
vaccin
gene
therapi
vector
progress
larg
depend
establish
reliabl
robust
analyt
assay
cope
high
number
sampl
particular
problem
determin
product
titer
requir
provis
suitabl
standard
biolog
technic
replic
assay
valid
logarithm
rang
latter
typic
result
compar
larg
error
typic
standard
deviat
method
viru
titer
assay
rang
log
accept
screen
ana
lysi
wellproven
oper
condit
one
point
facilit
effici
downstream
develop
good
model
tool
establish
appli
instanc
vicent
et
al
combin
steric
mass
action
model
ion
exchang
standard
chromatograph
column
model
simul
predict
adsorpt
elut
condit
viruslik
particl
anionexchang
aex
membran
adsorb
research
group
recent
describ
effect
ligand
densiti
aex
membran
adsorb
purif
recombin
baculovirus
compar
model
strategi
base
spr
spectroscopi
diethylaminoethyl
deae
ligand
densiti
membran
adsorb
method
indic
lower
ligand
densiti
increas
overal
yield
demonstr
spr
technolog
success
use
model
membran
adsorpt
process
studi
aid
theoret
model
predict
process
condit
dsp
improv
overal
studi
demonstr
chromatograph
model
combin
parallel
screen
techniqu
ration
design
experi
streamlin
design
optim
viral
dsp
futur
singleus
compon
individu
unit
oper
dsp
use
year
pharmaceut
industri
mainli
filtrat
buffermedia
storag
last
decad
relev
dispos
concept
extend
unit
oper
includ
chromatograph
applic
matric
membran
adsorb
monolith
recent
resin
use
drive
forc
increas
interest
singleus
concept
product
viral
vaccin
fast
highli
flexibl
set
product
process
expect
improv
respons
time
increas
vaccin
demand
pandem
prepar
addit
dispos
concept
limit
product
campaign
econom
attract
consid
current
good
manufactur
practic
cgmp
standard
raw
materi
equip
direct
contact
product
dedic
particular
product
process
furthermor
singleus
concept
commonli
reduc
elimin
timeconsum
costintens
process
step
clean
sanit
valid
howev
econom
applic
depend
heavili
scale
requir
individu
product
addit
avail
product
facil
henc
use
dispos
concept
alway
consid
bycas
basi
take
account
invest
cost
entir
variabl
run
cost
particular
manufactur
facil
individu
process
product
requir
recent
year
kit
smalland
mediumscal
purif
concentr
introduc
adenovirus
adenovirida
aav
parvovirida
lentivirus
retrovirida
eas
oper
compar
plasmid
purif
kit
requir
approxim
h
entir
process
major
manufactur
reli
adsorpt
membran
technolog
base
centrifug
devic
small
scale
syring
capsul
small
scale
larger
capsul
fast
protein
liquid
chromatographi
system
purif
lentiviru
aav
particl
mainli
achiev
use
aex
cationexchang
cex
membran
adsorb
accord
manufactur
handbook
maximum
capac
largest
unit
current
avail
approxim
total
viru
particl
adenoviru
aav
respect
infecti
particl
lentiviru
requir
cultur
volum
rang
ml
allow
recoveri
approxim
total
particl
depend
cultur
condit
viru
best
result
import
consid
viru
type
respect
kit
optim
howev
kit
use
viru
speci
adapt
oper
condit
importantli
nucleic
acid
ie
host
cell
dna
proteoglycan
also
bind
aex
membran
adsorb
potenti
coelut
henc
kit
procedur
often
includ
nucleas
treatment
harvest
reduc
nucleic
acid
contamin
improv
flow
rate
downstream
process
cell
culturederiv
viru
particl
thu
process
time
ie
kit
adenoviru
purif
addit
digest
step
use
chondroitinas
abc
enzym
degrad
glycosaminoglycan
side
chain
chondroitin
sulfat
proteoglycan
sometim
includ
remov
proteoglycan
contamin
certainli
puriti
result
viru
fraction
heavili
depend
cultur
condit
viru
speci
type
strain
well
appli
kit
therefor
detail
inform
viru
puriti
provid
manufactur
also
point
howev
virus
purifi
method
use
research
purpos
intend
clinic
studi
medic
applic
current
downstream
process
aim
combin
individu
unit
oper
overal
purif
train
take
account
viru
type
morpholog
specif
surfac
characterist
final
product
type
eg
subunit
vaccin
split
vaccin
inactiv
activ
viru
particl
applic
requir
contamin
level
product
yield
size
product
batch
develop
new
purif
scheme
equal
import
develop
optim
new
technolog
design
effici
dsp
train
base
optim
combin
new
technolog
current
use
method
unfortun
complet
purif
scheme
cultur
supernat
clinic
grade
viru
product
describ
detail
overal
recoveri
degre
contamin
literatur
henc
precis
evalu
respect
method
nearli
imposs
gener
howev
overal
viral
recoveri
greater
current
consid
accept
human
pharmaceut
product
particularli
challeng
issu
dsp
human
vaccin
purif
gene
therapi
vector
remov
host
cell
dna
current
guidelin
newli
licens
human
inact
vaccin
product
continu
cell
line
stipul
residu
dna
level
exceed
ng
per
dose
accept
level
contamin
host
cell
dna
gene
therapi
applic
even
lower
level
pg
residu
host
cell
dna
per
parenter
administ
dose
consid
accept
medic
agenc
mani
applic
level
achiev
via
nucleas
treatment
benzonas
clear
advantag
treatment
elimin
potenti
oncogen
function
dna
sequenc
even
low
amount
host
cell
dna
cleavag
nucleic
acid
adsorb
target
viru
addit
nucleas
condroitinas
treatment
frequent
result
improv
efficaci
gene
therapi
vector
purif
gene
therapi
vector
remov
empti
capsid
viru
particl
contain
nucleic
acid
sequenc
intend
genom
crucial
efficaci
howev
owe
small
differ
specif
surfac
characterist
viru
morpholog
fairli
difficult
success
separ
describ
via
densiti
centrifug
adenoviru
iec
aav
partial
deplet
hic
immobil
zincchel
interact
chromatographi
adenoviru
howev
possibl
applic
method
optim
consid
bycas
basi
substanti
challeng
dsp
viral
vaccin
gene
therapi
vector
biotechnolog
product
batchtobatch
variat
upstream
process
cell
cultur
harvest
vari
consider
product
concentr
qualiti
also
type
amount
contamin
effici
success
process
develop
aforement
issu
address
within
tightli
coupl
upand
downstream
process
therefor
critic
paramet
cultiv
process
effect
dsp
close
monitor
subsequ
purif
method
adapt
accordingli
follow
paragraph
summar
unit
oper
purif
train
differ
viru
type
describ
last
year
tabl
thorough
review
publish
luski
et
al
gmp
product
adenovir
vector
clinic
trial
anoth
overview
burova
loff
deal
chromatograph
purif
recombin
adenovir
aav
vector
gener
aec
drive
forc
describ
process
adenovirus
eglon
describ
purif
via
aec
combin
sec
clarifi
benzonasetr
cell
lysat
yield
total
viru
recoveri
compar
via
classic
csclpurif
method
duffi
et
al
compar
novel
membranebas
technolog
purif
adenoviru
aav
convent
techniqu
peixoto
et
al
describ
downstream
process
adenovir
vector
base
membran
technolog
purif
train
compris
clarif
ultrafiltr
aex
membran
adsorb
ultrafiltr
steril
filtrat
result
recoveri
infecti
particl
anoth
import
aspect
name
viru
aggreg
associ
dna
viru
particl
address
konz
et
al
wright
review
among
issu
vector
qualiti
characterist
aavrel
impur
eg
aavencapsid
dna
impur
pharmacolog
impact
well
gmp
consider
clinic
aav
vector
product
method
chromatograph
purif
train
aav
use
combin
hydroxyapatit
deaesepharos
cellufin
chisso
america
incorpor
rye
ny
usa
sulfat
overal
yield
describ
oriordan
et
al
recent
okada
et
al
describ
use
combin
cex
aex
membran
adsorb
purif
aav
serotyp
averag
recoveri
respect
downstream
process
strategi
purif
retrovir
vector
summar
least
two
excel
review
segura
et
al
andreadi
et
al
latter
publish
ahead
former
rodrigu
et
al
describ
purif
murin
leukemia
virusderiv
gene
therapi
vector
mean
membran
separ
aec
overal
review
recoveri
puriti
greater
rel
protein
concentr
moreov
lesch
et
al
illustr
scalabl
captur
step
lentivir
vector
gener
cell
baculovir
vector
captur
base
deae
monolith
column
reach
recoveri
ausubel
et
al
describ
cgmp
largescal
product
oncolyt
recombin
vesicular
stomat
viru
base
downstream
process
compos
primari
clarif
step
filtrat
benzonas
treatment
aec
diaultrafiltr
steril
filtrat
obtain
yield
individu
unit
oper
infecti
viru
particl
rang
approxim
steril
filtrat
fact
full
recoveri
obtain
complet
purif
batch
suggest
titer
estim
via
plaqu
form
assay
might
overestim
howev
overal
process
describ
comprehens
work
et
al
discuss
critic
point
affect
develop
product
clinic
grade
oncolyt
adenovirus
describ
upand
downstream
process
detail
illustr
downstream
process
compos
cell
lysi
triton
clarif
benzonas
treatment
aec
captur
ultradiafiltr
sec
ultradiafiltr
final
formul
follow
final
steril
filtrat
howev
achiev
puriti
yield
discuss
detail
downstream
process
purif
influenza
viru
particl
recent
review
summar
appli
purif
train
eggand
cell
culturederiv
influenza
viru
particl
wolff
reichl
motiv
recent
pandem
threat
influenza
numer
research
laboratori
work
optim
influenza
vaccin
product
process
downstream
side
center
attent
specif
chromatographi
media
substitut
frequent
appli
cellufin
sulfat
captur
influenza
viru
particl
use
chromatograph
matric
improv
volumetr
throughput
ie
monolith
membran
adsorb
wolff
et
al
describ
downstream
process
vaccinia
viru
base
combin
pseudoaffin
ionexchang
membran
adsorb
well
pseudoaffin
hic
matric
promis
downstream
train
result
overal
yield
infecti
viru
particl
furthermor
deplet
total
dna
start
materi
total
protein
amount
less
per
dose
achiev
howev
batch
variat
start
materi
result
signific
variat
product
yield
puriti
need
address
success
stori
vaccin
major
infecti
diseas
rest
histori
gene
therapi
contrast
rel
new
promis
technolog
revolut
molecular
genet
pave
way
success
medic
applic
vaccin
current
compris
rapidli
grow
market
within
biopharmaceut
industri
gene
therapi
vector
potenti
follow
line
nevertheless
vaccin
manufactur
capac
still
limit
ie
pandem
influenza
vaccin
gener
problem
relat
upsteam
process
dsp
effici
solv
consid
togeth
last
year
upstream
product
process
vaccin
move
away
respect
classic
system
usag
diploid
continu
cell
line
howev
downstream
purif
train
mani
case
adapt
new
requir
still
lack
optim
main
improv
vaccin
purif
govern
enhanc
throughput
capac
potenti
specif
individu
unit
oper
well
enhanc
link
appli
unit
oper
reduct
number
purif
step
process
develop
gene
therapi
vector
could
significantli
benefit
experi
accumul
vaccin
product
especi
vector
deriv
vaccin
nevertheless
still
sever
technic
problem
solv
product
class
benzonasefre
remov
host
cell
nucleic
acid
specif
difficulti
purif
gene
therapi
vector
high
final
vector
titer
remov
transduct
inhibitor
produc
cell
proteoglycan
glycosaminoglycan
elimin
free
envelop
protein
defectiveviru
particl
empti
capsid
remov
host
cell
protein
medium
protein
peptid
usual
less
problemat
equal
import
owe
potenti
allerg
reaction
note
reduc
start
level
processrel
protein
contamin
mainli
due
increas
usag
serumfre
proteinfre
even
fulli
defin
media
upstream
cultiv
excel
exampl
improv
overal
process
econom
via
tighter
coupl
upand
downstream
method
summari
downstream
process
describ
tabl
overal
yield
viru
particl
greater
product
human
vaccin
gene
therapi
applic
consid
satisfactori
purpos
higher
yield
achiev
depend
requir
product
puriti
type
amount
contamin
start
materi
exert
constant
pressur
toward
improv
product
qualiti
safeti
well
tighter
timelin
develop
bio
pharmaceut
certainli
push
effici
process
develop
current
advanc
field
indic
increas
applic
highthroughput
autom
scaleddown
model
combin
good
mathemat
model
experiment
design
process
develop
support
effort
certainli
advanc
also
requir
establish
highthroughput
assay
applic
parallel
screen
techniqu
ration
design
experi
develop
chromatograph
model
need
implement
support
downstream
process
dsp
develop
develop
applic
dsp
platform
technolog
improv
flexibl
respons
time
product
process
also
requir
overal
process
econom
need
enhanc
via
tighter
coupl
upstream
downstream
method
specif
captur
viru
particl
bioreactor
harvest
via
affin
chromatographi
optim
overal
dsp
combin
primari
concentr
purif
step
util
modern
chromatographi
matric
membran
adsorb
monolith
place
classic
resin
enabl
improv
product
numer
dsp
viral
particl
platform
precis
reliabl
process
character
result
unit
oper
avail
higher
specif
increas
volumetr
throughput
also
enabl
design
purif
train
reduc
number
step
advanc
dsp
like
involv
broader
use
filtrat
techniqu
eg
tangenti
flow
filtrat
diafiltr
avail
new
chromatographi
matric
membran
adsorb
monolith
bifunct
bead
identif
new
specif
ligand
furthermor
singl
use
concept
introduct
continu
dsp
method
play
import
role
well
tighter
process
integr
term
upand
downstream
process
furthermor
establish
platform
technolog
high
prioriti
wherea
larg
step
toward
platform
technolog
alreadi
accomplish
develop
downstream
purif
kit
gene
therapi
vector
addit
read
pedro
et
al
recent
publish
detail
summari
deal
purif
bionanoparticl
gagnon
publish
comprehens
descript
chromatograph
purif
viru
particl
segura
et
al
publish
overview
current
scalabl
method
purif
viral
vector
hammar
l
gilljam
g
extract
aqueou
system
obtain
highyield
aid
re
hum
retrovirus
morenweis
r
downstream
process
viral
vector
vaccin
gene
ther
